Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report)'s share price traded up 0.5% during trading on Friday . The stock traded as high as $6.22 and last traded at $6.18. 167,529 shares changed hands during trading, a decline of 25% from the average session volume of 224,004 shares. The stock had previously closed at $6.15.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the company. Stephens restated an "equal weight" rating and set a $6.00 price target on shares of Lifecore Biomedical in a research note on Friday, January 3rd. Craig Hallum raised their price target on Lifecore Biomedical from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Friday, November 22nd.
Check Out Our Latest Report on Lifecore Biomedical
Lifecore Biomedical Price Performance
The firm has a 50 day simple moving average of $6.17 and a 200-day simple moving average of $6.02. The company has a quick ratio of 1.21, a current ratio of 2.32 and a debt-to-equity ratio of 9.21. The company has a market cap of $228.81 million, a PE ratio of -11.04 and a beta of 0.96.
Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. As a group, research analysts predict that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.
Insider Buying and Selling at Lifecore Biomedical
In other Lifecore Biomedical news, CEO Paul Josephs purchased 17,000 shares of the stock in a transaction on Wednesday, January 8th. The stock was acquired at an average price of $5.74 per share, with a total value of $97,580.00. Following the completion of the acquisition, the chief executive officer now owns 559,717 shares in the company, valued at $3,212,775.58. The trade was a 3.13 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 32.20% of the stock is owned by insiders.
Institutional Investors Weigh In On Lifecore Biomedical
Several institutional investors have recently added to or reduced their stakes in LFCR. Legion Partners Asset Management LLC boosted its holdings in Lifecore Biomedical by 49.3% in the fourth quarter. Legion Partners Asset Management LLC now owns 4,431,823 shares of the company's stock worth $32,928,000 after acquiring an additional 1,463,414 shares in the last quarter. Greenhaven Road Investment Management L.P. boosted its holdings in Lifecore Biomedical by 62.2% in the fourth quarter. Greenhaven Road Investment Management L.P. now owns 3,616,146 shares of the company's stock worth $26,868,000 after acquiring an additional 1,387,362 shares in the last quarter. 325 Capital LLC boosted its holdings in Lifecore Biomedical by 57.9% in the fourth quarter. 325 Capital LLC now owns 2,162,466 shares of the company's stock worth $16,067,000 after acquiring an additional 792,681 shares in the last quarter. Invesco Ltd. acquired a new stake in Lifecore Biomedical in the fourth quarter worth about $4,128,000. Finally, DCF Advisers LLC boosted its holdings in Lifecore Biomedical by 87.2% in the fourth quarter. DCF Advisers LLC now owns 539,989 shares of the company's stock worth $4,012,000 after acquiring an additional 251,511 shares in the last quarter. Institutional investors and hedge funds own 83.36% of the company's stock.
Lifecore Biomedical Company Profile
(
Get Free Report)
Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.
Featured Stories
Before you consider Lifecore Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifecore Biomedical wasn't on the list.
While Lifecore Biomedical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
